Scalper1 News
Big pharma Bristol-Myers Squibb (BMY) said Monday that it’s dropping its effort to get its two-drug treatment for hepatitis C approved in the U.S., though it will continue pursuing other aspects of its hep C strategy. Bristol-Myers stock was down about 2% in morning trading on the stock market today. Bristol’s press release cited the “rapidly evolving hepatitis C treatment landscape” as the reason for withdrawing its FDA application for the Scalper1 News
Scalper1 News